戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of any insulin regimen (with or without oral antidiabetic drugs).
2  for the commercial synthesis of Januvia, an antidiabetic drug.
3 ment include metabolic-modulating agents and antidiabetic drugs.
4 ids and the thiazolidinedione (TZD) class of antidiabetic drugs.
5 get for the thiazolidinedione (TZD) class of antidiabetic drugs.
6 ell as the target of thiazolidinedione (TZD) antidiabetic drugs.
7 SKM G(q) signaling may prove useful as novel antidiabetic drugs.
8 get for the thiazolidinedione (TZD) class of antidiabetic drugs.
9 rget for the 2, 4-thiazolidinedione class of antidiabetic drugs.
10 o fatty acids, lipid-derived metabolites and antidiabetic drugs.
11 tients with retinopathy under treatment with antidiabetic drugs.
12 gate AD progression, probably by repurposing antidiabetic drugs.
13 e development of novel classes of GPCR-based antidiabetic drugs.
14 loads and the efficacy of GPR119 agonists as antidiabetic drugs.
15 ent the most recently approved class of oral antidiabetic drugs.
16 onylureas (SUs) are effective and affordable antidiabetic drugs.
17 s incident diabetes requiring treatment with antidiabetic drugs.
18 t signaling pathways may prove beneficial as antidiabetic drugs.
19 r the future discovery of GPR120 agonists as antidiabetic drugs.
20 ve useful for the development of efficacious antidiabetic drugs.
21 located 15kB upstream of SLC5A2, a target of antidiabetic drugs.
22 ere non-smokers, aged >/=40 years, and using antidiabetic drugs.
23 ated with basal insulin with or without oral antidiabetic drugs.
24 ed remission to a non-diabetic state and off antidiabetic drugs.
25 ared with commonly used combinations of oral antidiabetic drugs.
26 's disease compared to the use of other oral antidiabetic drugs.
27 glycemia through daily dosing of one or more antidiabetic drugs.
28 pment of better and safer PPARgamma-mediated antidiabetic drugs.
29 e 2 diabetes inadequately controlled on oral antidiabetic drugs.
30 uately controlled on basal insulin plus oral antidiabetic drugs.
31 d suggest an approach for the development of antidiabetic drugs.
32 merged as a major potential target for novel antidiabetic drugs.
33 rter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs.
34 1)R receptor agonist 2-MeS-ADP, as potential antidiabetic drugs.
35 te effects of the PPARgamma agonist class of antidiabetic drugs.
36 onse to thiazolidinediones (TZDs), which are antidiabetic drugs.
37 lar target of the thiazolidinedione class of antidiabetic drugs.
38 many bioactive natural products, such as the antidiabetic drug acarbose, the crop protectant validamy
39 ar IC(50) values, far lower than that of the antidiabetic drug acarbose.
40  selectively phosphorylate a clinically used antidiabetic drug, acarbose(1,2), resulting in its inact
41 f action is unique in that no other approved antidiabetic drugs act via this mechanism, and raises th
42 ollowing the recent therapeutic successes of antidiabetic drugs aimed at either mimicking GLP-1 or pr
43 t PPARgamma ligands are clinically effective antidiabetic drugs, although side effects limit their ut
44 relationship between cumulative use of other antidiabetic drugs and either outcome.
45 disorders, and discusses mechanisms by which antidiabetic drugs and metabolic interventions improve c
46 izes the anticancer drug paclitaxel, certain antidiabetic drugs, and endogenous substrates, including
47 -related diagnosis codes, cardiovascular and antidiabetic drugs, and obesity-related comorbidities.
48 e of the beneficial cardiac effects of these antidiabetic drugs are mediated, in part, by altered myo
49  that include the thiazolidinedione class of antidiabetic drugs, as well as derivatives of polyunsatu
50        Moreover, in subjects not taking oral antidiabetic drugs, baseline osteocalcin concentrations
51 s the next generation of insulin-sensitizing antidiabetic drugs, because the currently marketed PPARg
52       Metformin is among the most prescribed antidiabetic drugs, but the primary molecular mechanism
53                                          The antidiabetic drug canagliflozin is reported to possess s
54 enting a compelling strategy to identify new antidiabetic drug candidates.
55 f incretin-based drugs as compared with oral antidiabetic-drug combinations among patients with a his
56 drugs, as compared with those receiving oral antidiabetic-drug combinations, were estimated by means
57  receptor for the thiazolidinedione class of antidiabetic drugs, controls mitochondrial network fragm
58               Metformin (Met) is an approved antidiabetic drug currently being explored for repurposi
59 e receptor (GIPR) is an emerging strategy in antidiabetic drug development.
60 ch, it represents a target for anticancer or antidiabetic drug development.
61 iciency) led us to repurpose the widely used antidiabetic drug empagliflozin, an inhibitor of the ren
62 agon-like peptide 1 (GLP-1) receptor via the antidiabetic drug exenatide led to improvements in both
63              These data demonstrate that two antidiabetic drugs exert opposite effects on the PepT1 t
64  prescribed other diabetes treatments (other antidiabetic drug-exposed group).
65  PD compared to 517 individuals in the other antidiabetic drug-exposed group.
66 monotherapy with monotherapies of other oral antidiabetic drugs for assessing its efficacy and safety
67  lipid homeostasis and is the target for the antidiabetic drugs GI262570 and the thiazolidinediones (
68                                  Widely used antidiabetic drugs (GLP-1 receptor agonists and sulfonyl
69 istration industry guidance for licensing of antidiabetic drugs greatly increased the number of cardi
70    Improved management of antithrombotic and antidiabetic drugs has the potential to reduce hospitali
71 l-tolerated and Federal Drug Agency-approved antidiabetic drug, has positive effects on insulin resis
72  glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in
73 nists such as the thiazolidinedione class of antidiabetic drugs have a new target cell, the platelet.
74                                              Antidiabetic drugs have been found to have various effec
75  Because currently available antiobesity and antidiabetic drugs have limited efficacy and/or safety c
76 tive drugs, such as lipid-lowering drugs and antidiabetic drugs, have additional effects on stiffness
77 arious aspects related to the safety of oral antidiabetic drugs in cirrhosis); (3) the challenges in
78  with placebo, subcutaneous insulin, or oral antidiabetic drugs in people with type 1 or type 2 diabe
79 ibitors have been approved as a new class of antidiabetic drugs in type 2 diabetes mellitus, and stud
80  we tested the effects of metformin, an oral antidiabetic drug, in mice fed an HFD.
81 e, Lehraiki et al. report that metformin, an antidiabetic drug, inhibited melanogenesis, in vitro and
82 nism by which metformin, a widely prescribed antidiabetic drug, inhibits CARM1 activity.
83 ts with uncontrolled type 2 diabetes on oral antidiabetic drugs, initial injectable therapy with IDeg
84 azolidinedione class of insulin-sensitizing, antidiabetic drugs interacts with peroxisome proliferato
85                                          The antidiabetic drug Metformin (MET), one of the most preva
86                                          The antidiabetic drug metformin (which is derived from an he
87                        The widely prescribed antidiabetic drug metformin and the glycolytic inhibitor
88                                          The antidiabetic drug metformin consistently had the highest
89                           Treatment with the antidiabetic drug metformin during ovariectomy-induced w
90                                          The antidiabetic drug metformin exhibits both chemopreventiv
91                                   The common antidiabetic drug metformin has been shown to have prote
92 nts treated with sorafenib together with the antidiabetic drug metformin have a survival disadvantage
93                              Repurposing the antidiabetic drug metformin lowered pathogenic EZHIP, in
94                            The effect of the antidiabetic drug metformin on tumor growth was investig
95 ment of pregnant p53d/d mice with either the antidiabetic drug metformin or the antioxidant resveratr
96 that activation of AMPK with the widely used antidiabetic drug metformin or with the AMP mimetic 5-am
97                                          The antidiabetic drug metformin reduced mutant cell advantag
98                           Interestingly, the antidiabetic drug metformin reversed mTORC1 hyperactivat
99                                          The antidiabetic drug metformin stimulates AMP-activated pro
100                                          The antidiabetic drug metformin suppressed insulin-induced h
101 genous TAK1 was activated by oligomycin, the antidiabetic drug metformin, 5-aminoimidazole-4-carboxam
102 broad range of cationic drugs, including the antidiabetic drug metformin, into the urine and bile.
103 nefits of exercise and is the target for the antidiabetic drug metformin.
104 , and AMPK is the target for the widely used antidiabetic drug metformin.
105 n detail the effects of the most widely used antidiabetic drug metformin.
106 etabolic stress induced by starvation or the antidiabetic drug metformin.
107 e first time demonstrate a novel role of the antidiabetic drug, metformin, in suppressing uveitis in
108                    We also discuss promising antidiabetic drugs, molecular diagnostics currently in c
109 alated prodrugs of energy-disrupting Type II antidiabetic drugs namely, metformin and phenformin.
110  to the carboxylic acid group of the type II antidiabetic drugs nateglinide and meglitinide were synt
111          Treatment of diabetes includes oral antidiabetic drugs (OAD), insulin, or their combinations
112                          Troglitazone, a new antidiabetic drug of the thiazolidinedione class, acts a
113 ibenclamide and tolbutamide, two widely used antidiabetic drugs of the sulfonylurea (SU) family, show
114 ffective utilization of E. maxima as an oral antidiabetic drug or functional food ingredient with a p
115 l/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of
116 by either self-reported diagnosis, intake of antidiabetic drugs or insulin, or HbA1c >= 6.5%.
117 moglobin (Hb) A1c levels treated with 0 to 1 antidiabetic drug (OR: 1.68; 95% CI: 1.00-2.88), and wit
118 azole-4-carboxamide riboside (AICAR), by the antidiabetic drug phenformin, or by muscle contraction.
119                     We further show that the antidiabetic drug phenformin, which activates AMP kinase
120  debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bl
121             Binding of the thiazolidinedione antidiabetic drug pioglitazone led to the discovery of a
122 oup of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diaze
123                      The association between antidiabetic drug prescriptions and outcomes was assesse
124 complex I inhibitor metformin, a widely used antidiabetic drug, prevents TNF-induced mROS and necrosi
125 ylase kinase by a mechanism analogous to the antidiabetic drug proglycosyn.
126 d ( approximately 10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activato
127 rompted us to investigate the effects of two antidiabetic drugs, rosiglitazone and metformin, on PepT
128                        Glyburide (GLB) is an antidiabetic drug routinely used to treat gestational di
129  key intermediate in the preparation of oral antidiabetic drug Saxagliptin is discussed with an empha
130            Explorations of apoA-I as a novel antidiabetic drug should extend to treatments of diabeti
131    This important NR complex is a target for antidiabetic drugs since it binds to DNA and functions a
132 high excretion rates, high quantities of the antidiabetic drug sitagliptin (STG) enter wastewater tre
133                                          The antidiabetic drugs sitagliptin and exenatide, which inhi
134 -fat diet (HFD) fed rats and evaluated three antidiabetic drugs (Sitagliptin, Liraglutide, Saxaglipti
135 ed highly adaptable for the synthesis of the antidiabetic drug, sitagliptin, with a single carbon iso
136                                              Antidiabetic drugs such as peroxisome proliferator-activ
137  rational basis for the development of novel antidiabetic drugs targeting this class of receptors.
138 s help to further advance the development of antidiabetic drugs targeting this protein.
139               Troglitazone was a widely used antidiabetic drug that activates PPARgamma.
140 iazolidinedione derivative, is a widely used antidiabetic drug that binds and activates peroxisome pr
141                   Metformin is a widely used antidiabetic drug that exerts cardiovascular protective
142 eneration biguanide, is a commonly used oral antidiabetic drug that has been shown recently to stimul
143                   Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peri
144 r3 O(OCOEt)6 (OH2 )3 ](+) (A), a prospective antidiabetic drug that undergoes similar H2 O2 induced o
145 l can be gradually purged by the glitazones, antidiabetic drugs that are agonists of peroxisome proli
146 lar target of the thiazolidinedione class of antidiabetic drugs that has many side effects.
147      Thiazolidinediones are a novel class of antidiabetic drugs that improve insulin sensitivity in t
148                    Biguanides are a class of antidiabetic drugs that includes phenformin and metformi
149 e defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when cancer cell
150 rently studied as a potential new target for antidiabetic drug therapy.
151                                          The antidiabetic drugs thiazolidinediones bind and activate
152 lization and lectin analysis of acarbose, an antidiabetic drug, to dabsyl-tagged enzyme substrates to
153  200-fold scaling-up of the synthesis of the antidiabetic drug Tolbutamide, from hundreds of milligra
154                      Gram-scale synthesis of antidiabetic drugs tolbutamide and chlorpropamide in exc
155 r has been further highlighted by reports of antidiabetic drugs treating or promoting cancer.
156 ntiation following exposure to BDE-47 or the antidiabetic drug troglitazone (TROG).
157 utic options, from lifestyle intervention to antidiabetic drug use-including the most recent drug cla
158 which have the potential as antiasthmatic or antidiabetic drugs, we have synthesized and screened a v
159 to maximal metformin therapy, all noninsulin antidiabetic drugs were associated with similar HbA(1c)
160                                    All other antidiabetic drugs were discontinued on admission.
161 0 kg/m(2) or higher, on stable doses of oral antidiabetic drugs, were recruited from outpatient clini
162 armful consequence of this widely prescribed antidiabetic drug when used as a monotherapy in elderly
163                      Thiazolidinedione (TZD) antidiabetic drugs, which activate the peroxisome prolif
164  receptor for the thiazolidinedione class of antidiabetic drugs, which includes troglitazone and rosi
165 e development of GPR119 agonists as new oral antidiabetic drugs will be discussed.
166                  Metformin is the first-line antidiabetic drug with over 100 million users worldwide,
167  approach for the rational design of type II antidiabetic drugs with a reduced risk of contraindicate
168 he global epidemic in type 2 diabetes, novel antidiabetic drugs with increased efficacy and reduced s
169 tformin is the most commonly prescribed oral antidiabetic drug, with well-documented beneficial preve
170 a genomic occupancy and patient responses to antidiabetic drugs, with implications for developing per

 
Page Top